Search

Your search keyword '"Bonella F"' showing total 509 results
Start Over Author "Bonella F"
509 results on '"Bonella F"'

156. AB0181 Diffusing capacity and clinical characteristics of patients with systemic sclerosis – data from the german network for systemic sclerosis

Author

Moinzadeh, P, primary, Blank, N, additional, Siegert, E, additional, Henes, J, additional, Worm, M, additional, Sunderkoetter, C, additional, Schmalzing, M, additional, Kreuter, A, additional, Gunther, C, additional, Susok, L, additional, Zeidler, G, additional, Koetter, I, additional, Mueller-Ladner, U, additional, Krieg, T, additional, Juche, A, additional, Schmeiser, T, additional, Riemekasten, G, additional, Aberer, E, additional, Gaebelein-Wissing, N, additional, Distler, JHW, additional, Sárdy, M, additional, Pfeiffer, C, additional, Kuhr, K, additional, Hunzelmann, N, additional, Bonella, F, additional, and Kreuter, M, additional

Published
2017
Full Text
View/download PDF

163. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures

Author

University of Helsinki, Keuhkosairaudet (-2009), Campo, I., Luisetti, M., Griese, M., Trapnell, B.C., Bonella, F., Grutters, J., Nakata, K., Van Moorsel, C.H., Costabel, U., Cottin, V., Ichiwata, T., Inoue, Y., Braschi, A., Bonizzoni, G., Iotti, G.A., Tinelli, C., Rodi, G., Halme, Maija, University of Helsinki, Keuhkosairaudet (-2009), Campo, I., Luisetti, M., Griese, M., Trapnell, B.C., Bonella, F., Grutters, J., Nakata, K., Van Moorsel, C.H., Costabel, U., Cottin, V., Ichiwata, T., Inoue, Y., Braschi, A., Bonizzoni, G., Iotti, G.A., Tinelli, C., Rodi, G., and Halme, Maija

Published
2016

174. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives

Author

Kreuter, M. (Michael), Bonella, F. (Francesco), Wijsenbeek-Lourens, M.S. (Marlies), Maher, T.M. (Toby M.), Spagnolo, P. (Paolo), Kreuter, M. (Michael), Bonella, F. (Francesco), Wijsenbeek-Lourens, M.S. (Marlies), Maher, T.M. (Toby M.), and Spagnolo, P. (Paolo)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5-year survival of approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly heterogeneous disorder with a clinical course that varies from prolonged periods of stability to episodes of rapid deterioration. In the last decade, improved understanding of disease mechanisms along with a more precise disease definition has allowed the design and completion of a number of high-quality clinical trials. Yet, until recently, IPF was essentially an untreatable disease. Finally, pirfenidone and nintedanib, two compounds with antifibrotic properties, have consistently proven effective in reducing functional decline and disease progression in IPF. This is a major breakthrough for patients and physicians alike, but there is still a long way to go. In fact, neither pirfenidone nor nintedanib is a cure for IPF, and most patients continue to progress despite treatment. As such, comprehensive care of patients with IPF, including manage

Published
2015
Full Text
View/download PDF

175. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives

Author

Kreuter, M, Bonella, F, Wijsenbeek - Lourens, Marlies, Maher, TM, Spagnolo, P, Kreuter, M, Bonella, F, Wijsenbeek - Lourens, Marlies, Maher, TM, and Spagnolo, P

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5-year survival of approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly heterogeneous disorder with a clinical course that varies from prolonged periods of stability to episodes of rapid deterioration. In the last decade, improved understanding of disease mechanisms along with a more precise disease definition has allowed the design and completion of a number of high-quality clinical trials. Yet, until recently, IPF was essentially an untreatable disease. Finally, pirfenidone and nintedanib, two compounds with antifibrotic properties, have consistently proven effective in reducing functional decline and disease progression in IPF. This is a major breakthrough for patients and physicians alike, but there is still a long way to go. In fact, neither pirfenidone nor nintedanib is a cure for IPF, and most patients continue to progress despite treatment. As such, comprehensive care of patients with IPF, including management of comorbidities/complications and physical debility and timely referral for palliative care or, in a small number of highly selected patients, lung transplantation, remains essential. Several agents with high potential are currently being tested and many more are ready to be evaluated in clinical trials.

Published
2015

178. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good

Author

Wells, Au, Behr, J, Costabel, U, Cottin, V, Poletti, V, Richeldi, L, Albera, C, Ancochea, J, Antoniou, Km, Bonella, F, Bonniaud, P, Bouros, D, Bresser, P, Cordier, Jf, Crestani, B, Domagala Kulawik, J, Drent, M, Egan, Jj, Geiser, T, Grunewald, J, Grutters, J, Gudmundsson, G, Guenther, A, Harai, S, Harrison, Nk, Hirani, N, Hodgson, U, Kahler, Cm, Keane, Mp, Kiter, G, Kneussl, M, Maher, Tm, Mogulkoc, N, Muller Quernheim, J, Neurohr, C, Nunes, H, Parfrey, H, Peros Golubicic, T, Polychronopoulos, V, Prevot, G, Renzoni, Er, Robalo Cordeiro, C, Saltini, C, Skold, M, Spagnolo, P, Thomeer, M, Tomasseti, S, Valeyre, D, Vancheri, Carlo, Wallaert, B, Wuyts, W, and Xaubet, A.

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pathology, Statement (logic), Endpoint Determination, Settore MED/10 - Malattie dell'Apparato Respiratorio, Alternative medicine, Food and drug administration, Clinical endpoint, medicine, Maxim, Humans, Clinical Trials, Clinical Trials as Topic, Clinical Trials, Phase III as Topic, Disease Progression, Idiopathic Pulmonary Fibrosis, Research Design, Treatment Outcome, Set (psychology), Idiopathic pulmonary fibrosis, end-point in clinical trials, business.industry, respiratory system, Adversary, humanities, respiratory tract diseases, Phase III as Topic, Family medicine, Form of the Good, business
Abstract

The problem of the selection of accurate primary end-points for treatment studies in idiopathic pulmonary fibrosis (IPF) has recently been aired in a controversial paper from the USA.1 The limitations of current end-points are discussed and the authors conclude that all-cause mortality and all-cause nonelective hospitalisation best meet clinically meaningful end-point criteria. Much of the article is well argued and there is no quarrel with the view that current primary end-points are flawed. We also agree that all-cause mortality would, indeed, be the most clinically meaningful primary end-point and, therefore, the preferred primary end-point, were it not impractical, as discussed below. However, readers of the statement should reflect on the wise maxim that ‘the best may be the enemy of the good’. The purpose of our document is to provide a perspective on all-cause mortality as a primary end-point, endorsed by 52 European clinicians Including the authors (with one abstention), exploring the implications of the statement by Raghu and colleagues. We believe strongly that the adoption of the views of these authors by licensing bodies—with, by implication, a statistically significant mortality benefit a pre-requisite for drug registration—would set back progress in the treatment of IPF by a decade or more. It should be acknowledged at the outset that the statement of Raghu and colleagues does not make explicit recommendations with regard to drug licensing. Indeed, the authors declare that it is not their aim to make such recommendations and their intentions in this regard should not be questioned. However, if the statement has, indeed, been widely ‘misread’, the reasons for this are clear enough. Representatives of the US Food and Drug Administration (FDA) were active participants in a forum in Bethesda, Maryland (July 2011) which gave rise to the document as a proceedings statement.1 It is widely known …

Published
2012

181. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)

Author

Behr, J., additional, Bonella, F., additional, Bonnet, R., additional, Gläser, S., additional, Grohé, C., additional, Günther, A., additional, Koschel, D., additional, Kreuter, M., additional, Kirsten, D., additional, Krögel, C., additional, Markart, P., additional, Müller-Quernheim, J., additional, Neurohr, C., additional, Pfeifer, M., additional, Prasse, A., additional, Schönfeld, N., additional, Schreiber, J., additional, Wirtz, H., additional, Witt, C., additional, and Costabel, U., additional

Published
2015
Full Text
View/download PDF

190. Malattia di Erdheim-Chester

Author

Caramaschi, P., Biasi, Domenico, Lestani, M., Carletto, A., Bonella, F., and Bambara, Lisa Maria

Published
2004

194. Interstitial lung disease

Author

Antoniou, K. M., primary, Margaritopoulos, G. A., additional, Tomassetti, S., additional, Bonella, F., additional, Costabel, U., additional, and Poletti, V., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results